This post was contributed by a community member. The views expressed here are the author's own.

|Local Classified|Announcement|

Louis Lehot Dicusses the Medtech Deals 'Meaningfully Rebound' in Q1

Louis Lehot Dicusses the Medtech Deals 'Meaningfully Rebound' in Q1

Author: Louis Lehot, Foley & Lardner LLP

A PitchBook report shows a surge in MedTech M&A, particularly in cardiovascular tech and surgical robotics, with Q1 2024 seeing $3.3B in funding, up from $2.8B in Q4 2023. Cardiovascular and surgical robotics led the charge, with half of Q1 funding going to later-stage deals.

Read the full article here: The Medtech Deals 'Meaningfully Rebound' in Q1

Originally published on Axios

Author’s Bio:

Louis Lehot is a business lawyer and a partner at Foley & Lardner LLP, serving in Silicon Valley, San Francisco, and Los Angeles. Specializing in emerging growth companies, venture capital, and M&A, Louis is renowned for his expertise in providing practical legal strategies to entrepreneurs, innovative firms, and investors across various industries, including technology, digital health, life sciences, and clean energy. With a client portfolio ranging from public and private entities to financial sponsors and investment banks, Louis has facilitated numerous companies through formation, financing, governance challenges, and strategic transactions. Clients, colleagues, and industry guides alike commend Louis for his exceptional business acumen, legal proficiency, and leadership within Silicon Valley. Louis thrives on guiding his clients through every stage of growth, from garage to global, facilitating successful public offerings, and securing optimal liquidity events.

Connect and stay updated with Louis Lehot's latest insights and developments through the following platforms:

Read other recent and valuable articles written by Louis Lehot:

More Classifieds